Citius Oncology (NASDAQ:CTOR) officially transitioned from a development-stage clinical trial outfit to a revenue-generating commercial entity this quarter, posting its first sales of the newly approved immunotherapy LYMPHIR.
Helus Pharma (NASDAQ:HELP) reported financial results and clinical progress for the third quarter of fiscal 2026 ended December 31, 2025, highlighting a solid cash position and advancing late-stage programs targeting major psychiatric indications.
Beyond Air (NASDAQ:XAIR) reported a surge in third-quarter revenue and a strategic pivot toward its core respiratory business, announcing a binding agreement to divest its autism and neuro-oncology subsidiary to XTL Biopharmaceuticals.
Moderna (NASDAQ:MRNA) reported a massive full-year loss and revealed a significant regulatory setback in the U.S., as the Food and Drug Administration refused to review its experimental flu vaccine, complicating the biotech’s path to profitability.
West Pharmaceutical Services (NYSE:WST) shares gained momentum Thursday after the injectable-solution leader posted a fourth-quarter earnings beat and provided a bullish 2026 outlook, fueled by the explosive growth of GLP-1 "obesity" drugs and a massive jump in free cash flow.
Agios Pharmaceuticals (NASDAQ:AGIO) today released financial results and business updates for the fourth quarter and full year ended December 31, 2025, highlighting regulatory progress and commercial momentum in rare blood disorders.
Upstream Bio (NASDAQ:UPB) announced breakthrough results for its lead candidate, verekitug, in a mid-stage trial that could disrupt the multibillion-dollar biologics market for severe respiratory diseases.
Veru (NASDAQ:VERU) reported a significantly narrowed operating loss for the first fiscal quarter, as the biopharmaceutical firm pivots its resources toward a high-stakes clinical trial for its muscle-preserving obesity treatment.
Merck (NYSE:MRK) reached a historic milestone in oncology today as the FDA approved KEYTRUDA (pembrolizumab) and its new subcutaneous twin, KEYTRUDA QLEX, for the treatment of platinum-resistant ovarian cancer.
Agilent Technologies (NYSE:A) announced today that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx as the first and only companion diagnostic to identify first-line patients with epithelial ovarian cancer (EOC) eligible for Merck’s blockbuster immunotherapy, KEYTRUDA.
Tenet Healthcare (NYSE:THC) posted a sharp rise in fourth-quarter profitability, fueled by a surge in high-acuity surgical procedures and the strategic streamlining of its hospital portfolio.
Avantor (NYSE:AVTR) is betting on a structural overhaul to break a cycle of underperformance, unveiling its "Revival" transformation program alongside fourth-quarter results that showed persistent revenue pressure.
